Anzeige
Mehr »
Login
Freitag, 28.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien
Kritischer Rohstoff, strategische Wende: Warum diese Aktie jetzt auf das Radar kluger Investoren gehört
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PD78 | ISIN: BE0974340722 | Ticker-Symbol: 2SE
Frankfurt
28.03.25
08:02 Uhr
0,940 Euro
-0,006
-0,63 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
SEQUANA MEDICAL NV Chart 1 Jahr
5-Tage-Chart
SEQUANA MEDICAL NV 5-Tage-Chart
RealtimeGeldBriefZeit
0,9501,02020:53

Aktuelle News zur SEQUANA MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoSequana Medical NV: Press release: Sequana Medical to Attend the "VFB Happening 2025" in Ghent, Belgium on Saturday, 29 March 2025262Sequana Medical to Attend the "VFB Happening 2025" in Ghent, Belgium on Saturday, 29 March 2025 Ghent, Belgium - 27 March 2025 - Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana...
► Artikel lesen
20.03.Sequana Medical NV: Press release: Sequana Medical to Sponsor Liver Connect, 5th Annual Conference of Chronic Liver Disease Foundation325Sequana Medical to Sponsor Liver Connect, 5th Annual Conference of Chronic Liver Disease Foundation Ghent, Belgium - 20 March 2025 - Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or...
► Artikel lesen
19.03.Sequana Medical NV GAAP EPS of -€1.22, revenue of €0.106M2
18.03.Sequana Medical NV: Press release: Sequana Medical announces 2024 Full Year Results and 2025 Outlook602Sequana Medical announces 2024 Full Year Results and 2025 Outlook alfapump® - US FDA approval of alfapump® for the treatment of recurrent or refractory ascites due to liver cirrhosis; US commercial...
► Artikel lesen
SEQUANA MEDICAL Aktie jetzt für 0€ handeln
18.03.Sequana Medical NV: Press release: Sequana Medical Obtains Convertible Financing of EUR 4.0 Million from Major Shareholders and Committed Share Subscription Facility of up to EUR 60 Million from GEM290Sequana Medical Obtains Convertible Financing of EUR 4.0 Million from Major Shareholders and Committed Share Subscription Facility of up to EUR 60 Million from GEM Continued support from major shareholders...
► Artikel lesen
10.02.Sequana Medical NV: Press Release: Transparency Notification from Shareholders284Transparency Notification from Shareholders Ghent, Belgium - 10 February 2025 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment...
► Artikel lesen
03.02.Sequana Medical NV: Transparency Notifications from Shareholders374Transparency Notifications from Shareholders Ghent, Belgium - 3 February 2025 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment...
► Artikel lesen
24.01.Sequana Medical NV: Press release: Sequana Medical Announces New Share Capital Amount and New Number of Shares following Loan Conversions548SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES FOLLOWING LOAN CONVERSIONS Conversion of EUR 0.53 million under the Sensinnovat 2020 loan, EUR 1.28 million under...
► Artikel lesen
13.01.Sequana Medical NV: Press release: Transparency Notification from Shareholders394Transparency Notification from Shareholders Ghent, Belgium - 13 January 2025 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment...
► Artikel lesen
07.01.Sequana Medical NV: Press release: Six Month Data from alfapump Pivotal POSEIDON Study in Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis Published in American Journal of Gastroenterology1.428Six Month Data from alfapump® Pivotal POSEIDON Study in Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis Published in American Journal of Gastroenterology alfapump® system is...
► Artikel lesen
06.01.Sequana Medical NV: Press release: Sequana Medical Announces Key Opinion Leader (KOL) Webinar to Discuss alfapump US Commercial Roll-Out on January 8th at 15:00 CET / 09:00 EST480Sequana Medical Announces Key Opinion Leader (KOL) Webinar to Discuss alfapump® US Commercial Roll-Out on January 8th at 15:00 CET / 09:00 EST Webinar to discuss US commercial roll-out following...
► Artikel lesen
03.01.FDA approves Sequana Medical's Alfapump for ascites treatment2
23.12.24Sequana Medical: FDA Approves Alfapump For Treatment Of R/R Ascites Due To Liver Cirrhosis17
23.12.24Sequana Medical NV: Press release: Sequana Medical Announces US FDA Approval of alfapump for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis759Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis alfapump® is the first US approved active implantable medical device...
► Artikel lesen
20.12.24Sequana Medical NV: Press Release: Sequana Medical announces results of Extraordinary General Meeting of Shareholders and update on Convertible Financing464Sequana Medical announces results of Extraordinary General Meeting of Shareholders and update on Convertible Financing Ghent, Belgium - 20 December 2024 - Sequana Medical NV (Euronext Brussels:...
► Artikel lesen
06.12.24Sequana Medical NV: Press Release: Sequana Medical announces decision of major shareholders to invest in Second Tranche of Convertible Bridge Loan366SEQUANA MEDICAL ANNOUNCES DECISION OF MAJOR SHAREHOLDERS TO INVEST IN SECOND TRANCHE OF CONVERTIBLE BRIDGE LOAN Ghent, Belgium, 6 December 2024 - Sequana Medical NVand here). For more information...
► Artikel lesen
02.12.24Sequana Medical NV: Press Release: Sequana Medical announces update on second tranche of convertible bridge loan208SEQUANA MEDICAL ANNOUNCES UPDATE ON SECOND TRANCHE OF CONVERTIBLE BRIDGE LOAN Ghent, Belgium - 2 December 2024 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical")...
► Artikel lesen
27.11.24Sequana Medical NV: Press Release: Publication in Kidney Medicine Highlights Benefits of DSR 2.0 for Sequana Medical's Direct Sodium Removal Heart Failure Program and Board Composition Update584Publication in Kidney Medicine Highlights Benefits of DSR 2.0 for Sequana Medical's Direct Sodium Removal Heart Failure Program and Board Composition Update More efficient sodium and fluid removal...
► Artikel lesen
26.11.24Sequana Medical NV: Press Release: Transparency Notification from Shareholders391Transparency Notification from Shareholders Ghent, Belgium - 26 November 2024 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment...
► Artikel lesen
20.11.24Sequana Medical NV: Press Release: Sequana Medical announces Extraordinary General Meeting of Shareholders on 20 December 2024549Sequana Medical announces Extraordinary General Meeting of Shareholders on 20 December 2024 Ghent, Belgium - 20 November 2024 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company"...
► Artikel lesen
Seite:  Weiter >>
42 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1